Murrough, James W.
Abdallah, Chadi G.
Mathew, Sanjay J.
Article History
First Online: 17 March 2017
Competing interests
: In the past 3 years, J.W.M. has provided consultation services for Novartis, Janssen Research and Development, Genentech, ProPhase and Impel Neuropharma, has received research support from Avanir Pharmaceuticals, Inc., and is named on a pending patient for lithium to extend the antidepressant effect of ketamine and for the combination of lithium and ketamine for the treatment of suicidal ideation. The Icahn School of Medicine at Mount Sinai (to which J.W.M. is affiliated) is named on a patent and has entered into a licensing agreement and will receive payments related to the use of ketamine if it is approved for the treatment of depression. J.W.M. is not named on the patent and will not receive any payments. C.G.A. has served as a consultant and/or on advisory boards for Genentech and Janssen. S.J.M. has been receiving consulting fees from Acadia, Cerecor, Otsuka and Valeant, and is on an advisory board for VistaGen Therapeutics. He has received research support from Janssen Research & Development. He is supported by the use of facilities and resources at the Michael E. Debakey VA Medical Center, Houston, Texas, USA.